U.S. Markets closed

Is Athenex (ATNX) Stock Outpacing Its Medical Peers This Year?

Zacks Equity Research
HPT vs. HCP: Which Stock Is the Better Value Option?

Investors focused on the Medical space have likely heard of Athenex (ATNX), but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.

Athenex is a member of the Medical sector. This group includes 761 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ATNX is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for ATNX's full-year earnings has moved 3.56% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

Based on the latest available data, ATNX has gained about 21.45% so far this year. At the same time, Medical stocks have gained an average of 2.97%. This means that Athenex is outperforming the sector as a whole this year.

Looking more specifically, ATNX belongs to the Medical - Biomedical and Genetics industry, which includes 281 individual stocks and currently sits at #104 in the Zacks Industry Rank. Stocks in this group have gained about 0.72% so far this year, so ATNX is performing better this group in terms of year-to-date returns.

Investors with an interest in Medical stocks should continue to track ATNX. The stock will be looking to continue its solid performance.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Athenex, Inc. (ATNX) : Free Stock Analysis Report
To read this article on Zacks.com click here.